Plain-English translation of NCT07215663 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called in people with systemic lupus erythematosus (lupus), an autoimmune disease where the body's immune system attacks its own tissues. Researchers want to learn if this medication is safe to use, how the body processes it, and whether it helps reduce lupus symptoms and flares. This is an early-stage study, so the main focus is on safety and how well the treatment works as a first step.
Many people with lupus don't respond well enough to existing treatments and continue to have active disease despite being on medications. This trial aims to see whether the medication could offer a new option for people whose lupus hasn't been controlled by standard therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication (likely as an injection or infusion) and visit the study clinic multiple times to have your blood tested, be examined by doctors, and report how you're feeling. Researchers will carefully monitor you for any side effects and measure whether your lupus symptoms improve. The study involves multiple centers, meaning you'll go to a specialized clinic in your area, and it's an open-label study, which means both you and your doctors will know you're receiving the experimental medication rather than a placebo.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Candid Therapeutics
Enrollment target
~47 participants
Started
September 2025
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liu Tian
Candid Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.